blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4251128

EP4251128 - SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS MEMBRANE EMULSIFICATION [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  01.09.2023
Database last updated on 02.11.2024
FormerThe international publication has been made
Status updated on  04.06.2022
Formerunknown
Status updated on  05.01.2022
Most recent event   Tooltip24.07.2024Change - representative 
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6706 / US
[2023/40]
Inventor(s)01 / CHEN, Hunter
Tarrytown, NY 10591 / US
02 / ZHAO, Yiming
Tarrytown, NY 10591 / US
 [2023/40]
Representative(s)Reddie & Grose LLP
The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[N/P]
Former [2023/40]Roberts, Michael Austin
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
Application number, filing date21830837.724.11.2021
[2023/40]
WO2021US60800
Priority number, dateUS202063118264P25.11.2020         Original published format: US 202063118264 P
[2023/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022115588
Date:02.06.2022
Language:EN
[2022/22]
Type: A1 Application with search report 
No.:EP4251128
Date:04.10.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 02.06.2022 takes the place of the publication of the European patent application.
[2023/40]
Search report(s)International search report - published on:EP02.06.2022
ClassificationIPC:A61K9/00, A61K9/51, A61K9/50, A61K38/17, A61K47/06, A61K47/34
[2023/40]
CPC:
A61K9/0019 (EP,IL,KR); A61K9/5089 (EP,IL,KR); A61K38/179 (IL,KR,US);
A61K38/00 (EP,IL,KR); A61K47/06 (EP,IL); A61K47/34 (EP,IL);
A61K9/1658 (IL,US); A61K9/1694 (IL,US); A61K9/5015 (EP,IL);
A61K9/5031 (EP,IL,KR); C07K14/71 (EP,IL); C07K2319/30 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/40]
TitleGerman:FORMULIERUNGEN MIT VERZÖGERTER FREISETZUNG UNTER VERWENDUNG VON NICHT-WÄSSRIGER MEMBRANEMULGIERUNG[2023/40]
English:SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS MEMBRANE EMULSIFICATION[2023/40]
French:FORMULATIONS À LIBÉRATION PROLONGÉE À L'AIDE D'UNE ÉMULSIFICATION PAR MEMBRANE NON AQUEUSE[2023/40]
Entry into regional phase11.05.2023National basic fee paid 
11.05.2023Designation fee(s) paid 
11.05.2023Examination fee paid 
Examination procedure11.05.2023Examination requested  [2023/40]
11.05.2023Date on which the examining division has become responsible
01.09.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
22.11.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2017075072  (UNIV WYOMING [US]) [A] 1-45 * paragraph [001666]; claims 1,9,11,19,37 * * example - *;
 [XA]WO2017186073  (AC PHARMACEUTICALS CO LTD [CN]) [X] 28-30,40-44 * examples 1-30; claims 1-12 * * the whole document * [A] 1-27,31-39,45;
 [XPI]WO2021108548  (REGENERON PHARMA [US]) [XP] 1-45 * the whole document * * example -; claim - * [I] 1-45;
 [XA]  - HAN Y ET AL, "Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 378, no. 1-2, ISSN 0378-5173, (20090813), pages 159 - 166, (20090522), XP026348613 [X] 28-30,40-44 * figure 1 * * Materials and Methods * * the whole document * [A] 1-27,31-39,45
 [A]  - HOLT D J ET AL, "Synthesis of novel fluorous surfactants for microdroplet stabilisation in fluorous oil streams", JOURNAL OF FLUORINE CHEMISTRY, ELSEVIER, NL, vol. 131, no. 3, doi:10.1016/J.JFLUCHEM.2009.12.010, ISSN 0022-1139, (20100301), pages 398 - 407, (20100217), XP026912144 [A] 1-45 * page 402, column 2, paragraph 3.4 * * abstract * * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jfluchem.2009.12.010
by applicantUS4210529
 US4304767
 US4764364
 US5968543
 US6063910
 US6927044
 US7087411
 US7279159
 US7396664
 US7582298
 US7879984
 US7998477
 US8043617
 US8062640
 US8309088
 US8586713
 US8735095
 US2014271681
 US8871209
 US8945559
 US9018356
 US9079948
 US9132192
 US2015266966
 US9173880
 US9228014
 US2016017029
 US9260515
 US9265827
 US9302015
 US9353176
 US9402898
 US9447173
 US9453072
 US9475875
 US9540449
 US9587029
 US9637535
 US9657099
 US9657102
 US9718872
 US9771414
 US9795121
 US9938345
 US9987500
 US10125188
 US2019031741
    - RAGHUVANSHI, R. et al., Pharm Dev Technol, (19980000), vol. 3, no. 2, pages 269 - 76
    - ASHKENAZI et al., Proc. Natl. Acad. Sci. USA, (19910000), vol. 88, page 10535
    - BYRN et al., Nature, (19900000), vol. 344, page 677
    - HOLLENBAUGH et al., "Construction of Immunoglobulin Fusion Proteins", Current Protocols in Immunology, (19920000), pages 1 - 11
    - HUANG, C., Curr. Opin. Biotechnol., (20090000), vol. 20, pages 692 - 99
    - G. T. VLADISAVLJEVICR. A. WILLIAMS, Adv. Colloid Interface Sci., (20050000), vol. 113, no. 1, pages 1 - 20
    - LEE, M. et al., Lab Chip, (20140000), vol. 14, no. 3, pages 509 - 13
    - MARTINAC et al., J. Microencapsulation, (20050000), vol. 22, no. 5, pages 549 - 561
    - ASTETESABLIOV, Biomater. Sci. Polym. Ed., (20060000), vol. 17, no. 3, pages 247 - 89
    - LABETTHIELEMANS, Chemical Society Reviews, (20090000), vol. 38, pages 3484 - 3504
    - SINHA et al., Int. J. Pharm., (20040000), vol. 278, no. 1, pages 1 - 23
    - HELLERBARR, Biomacromolecules, (20040000), vol. 5, no. 5, pages 1625 - 32
    - HELLER, Adv. Drug. Deliv. Rev., (20050000), vol. 57, pages 2053 - 62
    - BUSTAMI et al., Pharma. Res., (20000000), vol. 17, pages 1360 - 66
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.